Fziomed Receives FDA 510(k) Clearance for Dynavisc® Tendon Protector Marking a Major Advancement in Surgical Solutions

Fziomed's Dynavisc® Tendon Protector Approved by the FDA



Fziomed, Inc., a prominent player in postsurgical adhesion prevention and biomaterials, has recently announced its receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Dynavisc® Tendon Protector. This clearance signifies a triumphant return for Fziomed as it expands its range of innovative surgical technologies in the United States.

Dynavisc is a fully synthetic and absorbable gel specifically engineered to safeguard tendons, ligaments, and skeletal muscles after surgical procedures. With a focus on minimizing postoperative complications, Dynavisc plays an essential role in optimizing healing.

Utilizing Fziomed's proprietary dual-polymer technology, Dynavisc offers surgeons a ready-to-use solution that can be applied to the surgical site following tendon repairs. By forming a protective barrier around the exposed tissues, it aids in reducing pain and maintaining mobility, which ultimately improves patient recovery outcomes.

Ryan Bledsoe, Vice President of Marketing and Market Access at Fziomed, highlighted the importance of this FDA clearance, stating, “This represents another important milestone for Fziomed as we continue expanding our portfolio of innovative biomaterial technologies in the United States.” He also emphasized the gel's long history of success in international markets and its proven effectiveness in enhancing surgical recovery.

With over a decade in clinical use and a track record of treating more than 50,000 patients worldwide, Dynavisc demonstrates a robust clinical foundation supported by numerous peer-reviewed studies. These investigations have evaluated its effectiveness in improving functional outcomes and tissue healing post-surgery.

Dr. Nicholas Caggiano, an Orthopedic Hand Surgeon at Central Coast Orthopedic Medical Group in San Luis Obispo, emphasized the challenges posed by postoperative scar tissue, which can hinder tendon movement and negatively impact surgical success. “Having a gel technology that creates a temporary protective barrier between tissues is a valuable addition to our surgical options,” Dr. Caggiano noted. He also praised the gel's ease of application, suggesting it seamlessly integrates into existing surgical workflows.

The clearance of Dynavisc also underscores Fziomed’s commitment to introducing proven biomaterial technologies to U.S. surgeons, addressing challenges that arise after surgery across various specialties.

About Fziomed, Inc.
Founded in 1996, Fziomed is recognized as a leader in the field of biomaterials, having aided over one million patients globally. The company focuses on developing, manufacturing, and commercializing high-quality surgical biomaterials intended to enhance patient outcomes. By specializing in adhesion prevention across multiple surgical contexts—such as spine, tendon, nerve, abdominal, pelvic, and intrauterine procedures—Fziomed is dedicated to meeting clinical needs that often go unmet.

Fziomed’s innovative synthetic and absorbable gel formulations are crafted from its proprietary dual-polymer technology, promoting a physical separation of tissues during the natural healing process. With its portfolio of adhesion barrier products available in over 70 countries since 2002, Fziomed continues to drive surgical excellence in patient care.

Conclusion
As Fziomed proudly expands its presence in the U.S. market, the approval of Dynavisc signifies the company’s ongoing dedication to medical innovation and the improvement of surgical outcomes for patients worldwide. Fziomed remains at the forefront of medical technology, aiming to transform postoperative care through its advanced solutions. For more information on Fziomed and its array of industry-leading products, please visit fziomed.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.